Abstract
The AVOID (Aliskiren in the eValuation of prOteinuria In Diabetes) study is the first study which looked at the kidney-protective benefits of oral direct renin inhibitor aliskiren, independent of its proven blood pressure reductions. Total 599 type 2 diabetic hypertensive patients were involved in multinational, randomized and double-blind study.
After 6 months of treatment with aliskiren (initially 150 mg and then increased to 300 mg) or placebo, in addition to losartan (100 mg) and optimising blood pressure treatment, 20% reduction in albuminuria was seen in aliskiren subgroup.